Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review

Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review

  • Products Id :- GDPH57988FSA
  • |
  • Pages: 38
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Imugene Ltd (IMU)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immune-oncology. The company focuses on developing immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various tumors including gastric, breast, ovarian and pancreatic cancers. Imugene's lead product candidate, HER-Vaxx is a HER-2+ cancer immunotherapy in Phase II clinical trials for the treatment of gastric cancer and completed Phase I clinical trials for the treatment of breast cancer. The company develops its vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes that recognized by an antibody with antitumor activity. Imugene is headquartered in Melbourne, Victoria, Australia.

Imugene Ltd Key Recent Developments

Oct 01,2018: Imugene names Professor Pravin Kaumaya to Scientific Advisory Board

Sep 23,2018: Imugene appoints gastrointestinal cancer expert to Scientific

Sep 23,2018: Imugene appoints gastrointestinal cancer expert to Scientific

Sep 23,2018: Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

Sep 23,2018: Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Imugene Ltd-Key Facts 5

Imugene Ltd-Key Employees 6

Imugene Ltd-Key Employee Biographies 7

Imugene Ltd-Major Products and Services 8

Imugene Ltd-History 9

Imugene Ltd-Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2-Company Analysis 12

Company Overview 12

Imugene Ltd-Business Description 13

Imugene Ltd-Corporate Strategy 14

Imugene Ltd-SWOT Analysis 15

SWOT Analysis-Overview 15

Imugene Ltd-Strengths 15

Imugene Ltd-Weaknesses 16

Imugene Ltd-Opportunities 17

Imugene Ltd-Threats 18

Imugene Ltd-Key Competitors 19

Section 3-Company Financial Ratios 20

Financial Ratios-Capital Market Ratios 20

Financial Ratios-Annual Ratios 21

Performance Chart 23

Financial Performance 23

Financial Ratios-Interim Ratios 24

Financial Ratios-Ratio Charts 25

Section 4-Company's Lifesciences Financial Deals and Alliances 26

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27

Imugene Ltd, Recent Deals Summary 28

Section 5-Company's Recent Developments 29

Jul 31, 2018: Imugene: Business Update-Appendix 4C for the quarter ended 30 June 2018 29

Jul 31, 2018: Imugene: Business Update-Appendix 4C for the quarter ended 30 June 2018 30

Jul 23, 2018: Imugene: PD-1 cancer vaccine development update 31

Mar 28, 2018: Leslie Chong Appointed as Managing Director 32

Oct 10, 2017: Imugene Receives USD 1.1 million in Research and Development Tax Refund 33

Section 6-Appendix 34

Methodology 34

Ratio Definitions 34

About GlobalData 38

Contact Us 38

Disclaimer 38

List of Figures

Imugene Ltd, Performance Chart (2013-2017) 23

Imugene Ltd, Ratio Charts 25

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26

Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 27

List of Tables

Imugene Ltd, Key Facts 5

Imugene Ltd, Key Employees 6

Imugene Ltd, Key Employee Biographies 7

Imugene Ltd, Major Products and Services 8

Imugene Ltd, History 9

Imugene Ltd, Subsidiaries 11

Imugene Ltd, Key Competitors 19

Imugene Ltd, Ratios based on current share price 20

Imugene Ltd, Annual Ratios 21

Imugene Ltd, Annual Ratios (Cont...1) 22

Imugene Ltd, Interim Ratios 24

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27

Imugene Ltd, Recent Deals Summary 28

Currency Codes 34

Capital Market Ratios 34

Equity Ratios 35

Profitability Ratios 35

Cost Ratios 36

Liquidity Ratios 36

Leverage Ratios 37

Efficiency Ratios 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Prescient Therapeutics Ltd

Prana Biotechnology Ltd

Antisense Therapeutics Ltd

Alchemia Ltd

Activistic Ltd

Imugene Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8625
Site License
USD 250 INR 17250
Corporate User License
USD 375 INR 25875



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]